Mary Ann Gray, PhD
Mary Ann Gray, PhD was elected to our Board in December 2018. She also serves as a member of the Audit, Compensation and Nominating and Corporate Governance committees.
Dr. Gray has extensive experience in the biotechnology and biopharmaceutical industry. She has served on the boards of Senomyx and Juniper Pharmaceuticals, a women’s health company; TetraLogic, a publicly held, clinical-stage biopharmaceutical company focused on oncology and infectious diseases; Dyax, a rare disease company acquired by Shire in 2016; and ACADIA Pharmaceuticals, focused on commercialization of CNS therapies. She is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm.
Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes. She began her career in biotechnology as a scientist focused on new drug development. She subsequently worked in equities research before becoming a senior analyst and portfolio manager.
She holds a BS from University of South Carolina and a PhD in pharmacology from the University of Vermont. She completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.